Liquidia (NASDAQ:LQDA) Director Stephen Bloch Sells 318,893 Shares

Liquidia Corporation (NASDAQ:LQDA) Director Stephen Bloch sold 318,893 shares of the firm’s stock in a transaction that occurred on Monday, May 11th. The shares were sold at an average price of $50.23, for a total transaction of $16,017,995.39. Following the completion of the sale, the director directly owned 1,870,042 shares of the company’s stock, valued at approximately $93,932,209.66. This represents a 14.57% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Liquidia Stock Performance

Shares of Liquidia stock opened at $57.59 on Thursday. The firm has a 50 day simple moving average of $38.70 and a 200 day simple moving average of $35.54. The company has a debt-to-equity ratio of 1.18, a current ratio of 2.22 and a quick ratio of 1.84. Liquidia Corporation has a fifty-two week low of $11.85 and a fifty-two week high of $57.80. The firm has a market cap of $5.12 billion, a P/E ratio of 411.39 and a beta of 0.41.

Liquidia (NASDAQ:LQDA) last released its earnings results on Monday, May 11th. The company reported $0.52 EPS for the quarter, topping analysts’ consensus estimates of $0.41 by $0.11. The firm had revenue of $132.87 million during the quarter, compared to analyst estimates of $119.44 million. Liquidia had a net margin of 7.74% and a return on equity of 46.82%. The business’s quarterly revenue was up 4187.1% compared to the same quarter last year. Sell-side analysts predict that Liquidia Corporation will post 2.14 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on LQDA. Zacks Research raised shares of Liquidia from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, May 5th. Wall Street Zen raised shares of Liquidia from a “hold” rating to a “buy” rating in a research report on Saturday, March 7th. HC Wainwright boosted their price objective on shares of Liquidia from $55.00 to $67.00 and gave the company a “buy” rating in a research report on Tuesday. Needham & Company LLC boosted their price objective on shares of Liquidia from $54.00 to $70.00 and gave the company a “buy” rating in a research report on Monday. Finally, Jefferies Financial Group reaffirmed a “buy” rating and issued a $60.00 price objective on shares of Liquidia in a research report on Monday. Three investment analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $49.33.

Institutional Investors Weigh In On Liquidia

Several institutional investors and hedge funds have recently added to or reduced their stakes in LQDA. Northwestern Mutual Wealth Management Co. bought a new stake in Liquidia during the 4th quarter worth about $25,000. NewEdge Advisors LLC acquired a new position in shares of Liquidia during the 2nd quarter worth about $25,000. Skandinaviska Enskilda Banken AB publ acquired a new position in shares of Liquidia during the 3rd quarter worth about $30,000. FNY Investment Advisers LLC acquired a new position in shares of Liquidia during the 3rd quarter worth about $34,000. Finally, Covestor Ltd increased its stake in shares of Liquidia by 41.9% during the 4th quarter. Covestor Ltd now owns 1,216 shares of the company’s stock worth $42,000 after purchasing an additional 359 shares during the last quarter. 64.54% of the stock is owned by institutional investors.

Trending Headlines about Liquidia

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: Liquidia reported first-quarter results that beat expectations on both earnings and revenue, reinforcing the view that commercialization is gaining traction and that profitability is improving. Liquidia Corporation Reports First Quarter 2026 Financial Results
• Positive Sentiment: Management said YUTREPIA net product sales rose 44% sequentially and projected at least $1 billion in net revenue by 2027, which signals a long growth runway if launch momentum continues. Article on YUTREPIA sales and 2027 revenue target
• Positive Sentiment: Several analysts turned more constructive after the earnings report, including Needham, BTIG, and Wells Fargo, with higher price targets and buy ratings helping support the stock. Needham price target raise
• Positive Sentiment: Liquidia was also added to Zacks’ Rank #1 “Strong Buy” list, adding to the bullish momentum around the shares. Zacks Strong Buy list
• Neutral Sentiment: CEO Roger Jeffs and Director Stephen M. Bloch both disclosed insider stock sales, but the CEO’s sale was under a pre-arranged 10b5-1 plan and the transactions are being viewed more as monitoring points than as clear operating red flags. SEC filing
• Negative Sentiment: One research note argued that YUTREPIA’s launch upside may be approaching a ceiling, suggesting some investors may worry the current growth rate becomes harder to sustain. Rating downgrade article

Liquidia Company Profile

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).